Spero Therapeutics, Inc., was incorporated in December 2013 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company focused on identifying and developing new therapies for rare diseases and diseases with high unmet need. The company's clinical stage product candidate teipenem HBr has completed its second Phase 3 trial and has the potential to be the first oral carbapenem for the treatment of adult patients with complex urinary tract infections caused by certain microorganisms, including pyelonephritis.
